Inhibrx, Inc.
Healthcare · Biological Products, (No Diagnostic Substances) · CA · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY23 | FY22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|
| Revenue | $1.8M | $2.2M | $7.2M | $12.9M | $13.2M |
| Operating income | −$219.2M | −$129.1M | −$76.6M | −$67.4M | −$43.7M |
| Net income | −$241.4M | −$145.2M | −$81.8M | −$76.1M | −$51.4M |
| Total assets | $307.9M | $290.9M | $150.4M | $143.7M | $26.5M |
| Total liabilities | $264.4M | $232.8M | $98.1M | $68.3M | $60.6M |
| Equity | $43.5M | $58.1M | $52.4M | $75.5M | −$93.6M |
| EPS (diluted) | $-5.12 | $-3.62 | $-2.15 | $-3.01 | — |
| Shares out. | 43.6M | 39.0M | 37.7M | 37.7M | 18.2M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2023- Operating margin
- −12178.9%
- Net margin
- −13408.9%
- Return on equity
- −554.8%
- Return on assets
- −78.4%
- Return on capital (ROCE)
- −87.1%
- Liabilities / assets
- 85.9%
- Debt / equity
- 6.08×
- Book value / share
- $1.00
- Revenue growth (YoY)
- −17.9%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2023- Altman Z″ (distress)
- -6.02distress
- Accruals / assets
- −15.6%clean
- Piotroski F-Score
- 1/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 5 warning● 1 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 2Active Not Recruitingreadout ~2025-09-30Study of INBRX-109 in Conventional Chondrosarcoma
- Phase 1/2Active Not Recruitingreadout ~2026-10-30Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- Phase 1Recruitingreadout ~2028-12Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
- Phase 2/3Active Not Recruitingreadout ~2029-05INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Other material eventMay 30, 2024
- Shareholder vote · Regulation FD disclosure · Other material eventMay 24, 2024
- Other material eventMay 17, 2024
- Results of operationsMay 9, 2024
- Other material eventMay 8, 2024
- Other material eventMar 12, 2024
- Results of operationsFeb 28, 2024
- Entered a material agreement · Regulation FD disclosureJan 23, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/ANov 14, 2024
- 15-12GJun 10, 2024
- SC 13G/AJun 3, 2024
- 4Jun 3, 2024
- 4May 31, 2024
- 4OWNERSHIP DOCUMENTMay 30, 2024
- 4OWNERSHIP DOCUMENTMay 30, 2024
- 4OWNERSHIP DOCUMENTMay 30, 2024
- 4OWNERSHIP DOCUMENTMay 30, 2024
- 4OWNERSHIP DOCUMENTMay 30, 2024
- 4OWNERSHIP DOCUMENTMay 30, 2024
- 4OWNERSHIP DOCUMENTMay 30, 2024
- S-8 POSMay 30, 2024
- S-8 POSMay 30, 2024
- S-8 POSMay 30, 2024
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.